Guardant Health, Inc. (GH)
適正価値ファンダメンタル
47
株価
$176.61
時価総額
$23.94B
パート1 · 企業の価値
概要
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults. In addition, the company offers GuardantINFINITY test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantOMNI test covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications; GuardantINFORM, which provides longitudinal biological insight into tumor evolution alongside longitudinal clinical outcomes; and GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies. Further, it provides Smart Platform, which delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic. Additionally, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. It has a strategic collaboration with Nuvalent, Inc. for oncology drug development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 2026年9月18日 with claude-haiku-4-5 — shared with all users
Natera's Signatera is the market-leading blood test for molecular residual disease after cancer surgery, competing directly with Guardant Reveal for the same oncologists and the same post-treatment monitoring reimbursement.
Tempus sells the xF+ liquid biopsy panel and tissue profiling to the same oncology practices, competing with Guardant on both therapy selection and residual disease testing.
A wholly owned Roche subsidiary whose FoundationOne Liquid CDx and FoundationOne CDx panels are the closest rivals to Guardant360 for comprehensive genomic profiling used to pick a cancer therapy.
Acquired by Abbott in March 2026 and no longer separately listed, Exact Sciences sells Cologuard and its own blood-based colorectal screening test to the same primary-care physicians Guardant targets with Shield.
Caris competes for the same oncologists' test orders with whole-exome tissue profiling and its Caris Assure blood platform, covering therapy selection and residual disease alongside Guardant.
GRAIL's Galleri is the leading multi-cancer blood screening test, competing with Guardant's Shield franchise for the same asymptomatic screening population and employer or health-system contracts.
貸借対照表と流動性
売上高
$1.18B
直近12か月（2026/6/30まで）
純利益
$-453M
直近12か月（2026/6/30まで）
フリーキャッシュフロー
$-233M
自己資本合計
$-99M
負債合計
$2.11B
流動比率
4.03
利払い倍率
97.65
負債/EBITDA
-
一株当たり利益（EPS）
売上高と純利益
フリーキャッシュフロー
収益内訳
財務推移表
利益率の推移
負債の推移
負債の重さ
成長率グリッド
成長率 — 売上高
適正価値の推定
適正価値
$197.04
現在株価
$176.61
安全マージン
+10.4%
適正価値レンジ
$187.19 - $206.89
使用した評価手法間のばらつきであり、統計的に較正された信頼区間ではありません。
推定方法
バリュエーション指標
P/E レシオ
-
ROE
419.2%
P/B レシオ
-
P/FCF
-
粗利益率
65.0%
ROIC
-23.6%
収益性レーダー
価値創造（経済的モート）
ROIC
-23.6%
WACC
13.1%
ROIC − WACC
-36.7 pp
ROICが資本コストを下回っています。投資した1ドルごとに企業は価値を破壊しています。
ファンダメンタル分析基準
合格（11）
- EPS shows upward trend
- Price CAGR 21.31%
- Gross Margin 65.0%
- Current Ratio
- Interest Coverage
- Low reliance on intangibles
- Revenue Growth 5Y 27.9%
- Analyst Consensus 91% Buy
- Share Dilution 2.3%
- Net Margin Trend -38.3% vs -49.9%
- Piotroski F-Score 5/9
不合格（7）
- ROIC -23.6%
- Operating Margin -39.7%
- Positive Free Cash Flow
- Return on Tangible Assets
- DCF valuation (Unknown)
- ROE -246.6%
- Earnings Surprise avg -7.2%
データなし（9）
- P/FCF NaN
- P/B Ratio NaN
- Dividend Payout NaN%
- Debt/Equity ratio
- CapEx intensity
- Debt/EBITDA
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-スコア
まちまちのシグナル：一部の領域に注意が必要
利益の質
低品質：会計処理を調査してください
株式希薄化
新株を発行しており、所有権を希薄化している
機関投資家の保有
ガバナンス
経営陣
| 氏名 | 役職 | 年齢 |
|---|---|---|
| Dr. Helmy Eltoukhy Ph.D. | Co-Founder, Co-CEO & Chairman | 46 |
| Dr. AmirAli Talasaz Ph.D. | Co-CEO & Director | 45 |
| Mr. Michael Bell | Chief Financial Officer | 56 |
| Dr. Darya Chudova | Chief Technology Officer | 51 |
| Mr. John G. Saia J.D. | Chief Legal Officer & Corporate Secretary | 52 |
| Mr. Andy Ament | Senior Vice President of Operations | - |
| Mr. Kumud Kalia | Chief Information Officer | 59 |
| Zarak Khurshid | Vice President of Investor Relations | - |
| Ms. Gulshan Shaver J.D. | Senior VP of Legal Affairs & Chief Compliance Officer | - |
| Ms. Jennifer Higgins | Senior Vice President of Public Affairs | - |
監査リスク
1
取締役会リスク
7
報酬リスク
7
株主権利リスク
8
パート2 · 株価と買い時
この部分は企業に価値があるかを判断するものではありません。ファンダメンタルズに納得したうえで、いつ買うかを選ぶためのものです。内容：テクニカル分析、ポテンシャル、過去のドローダウン、ガンマエクスポージャー。
業績推移
via SEC EDGAR
Latest News
Recent headlines for GH, sourced from Markets Gazette.
- 5/20/2026POSITIVEGuardant Health Secures FDA Approval For Expanded Liquid Biopsy Test
Guardant Health has received FDA approval for an expanded use of its Guardant360 Liquid CDx test. This blood-based cancer profiling tool now offers broader diagnostic capabilities, a significant step forward in non-invasive oncology diagnostics. The expanded approval is expected to enhance the test's utility for a wider range of cancer patients and treatment decisions. For investors, this regulatory milestone signifies strong product development and market potential, potentially leading to increased adoption and revenue growth for Guardant Health.
via Markets Gazette